Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002659
Status:
UNKNOWN
Last Update Posted:
2013-12-19
First Post:
1999-11-01
Brief Title:
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
Sponsor:
Matrix Pharmaceutical
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
CDR0000064225
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Matrix Pharmaceutical
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None